New medicines for tropical diseases in pregnancy: Catch-22

PLoS Medicine

Volumn 5, Issue 6, 2008, Pages 0843-0844

  White, Nicholas J ^a,b   McGready, Rose M ^a,b,c   Nosten, François H ^a,b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; FANSIDAR; PRIMAQUINE; PROGUANIL; TETRACYCLINE DERIVATIVE; THALIDOMIDE; ANTIINFECTIVE AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE;

DEVELOPING COUNTRY; DRUG CONTRAINDICATION; DRUG SAFETY; FEMALE; HUMAN; MALARIA; MATERNAL MORTALITY; MATERNAL WELFARE; PREGNANCY; PREGNANT WOMAN; RISK ASSESSMENT; SHORT SURVEY; TERATOGENICITY; TROPICAL DISEASE; EVALUATION; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; REVIEW; TROPIC CLIMATE; TROPICAL MEDICINE;

ANTI-INFECTIVE AGENTS; ARTEMISININS; FEMALE; HUMANS; MALARIA; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY COMPLICATIONS, PARASITIC; TROPICAL CLIMATE; TROPICAL MEDICINE;

EID: 46349096413     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050133     Document Type: Short Survey

References (12)

1. World Health Organization (2007) Maternal mortality in 2005. Estimates developed by WHO, UNICEF, UNFPA and the World Bank. Available: hltp://www.who.int/reproductive-healt/publications/maternal_mortality_2005/ mme_2005.pdf Accessed 8 May 2008.
2. Fisk NM, Atun R (2008) Market failure and the poverty of new drugs in maternal health. PLoS Med 5: e22. doi: 10.1371/journal. pmed.0050022
3. Desai M, ter Kuile FO, Nosten F. McGready R, Asamoa K, et al. (2007) Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7: 93-104.
4. Myint HY, Tipmanee P, Nosten F, Day NP, Pukrittavakamee S, et al. (2004) A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 98: 73-81.
5. Tagbor HK, Chandramohan D, Greenwood B (2007) The safety of amodiaquine use in pregnant women. Expert Opin Drug Saf 6: 631-635.
6. Ward SA. Sevene EJ, Hastings IM, Nosten F, McGready R (2007) Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7: 136-144.
7. Barnes K, Watkins WM, White NJ (2008) Antimalarial dosing regimens and drug resistance. Trends Parasitol 4: 127-134
8. Green MD, van Eijk AM, van Ter Kuile FO, Ayisi JG, Parise ME, et al. (2007). Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Infect Dis. 196: 1403-1408.
9. China Cooperative Research Group on qinghaosu and its derivatives as antimalarials (1982) Studies on the toxicity of qinghaosu and its derivatives. J Tradit Chin Med 2: 31-38.
10. Longo M, Zanoncelli S, Manera D, Brughera M, Colombo P. et al. (2006) Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro, Reprod Toxicol 21: 83-93.
11. Dondorp A, Nosten F, Stepniewska K, Day N, White NJ, etal. (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717-725.
12. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, PIowe CV, et al (2007) World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology. Malar J 6: 122.